Alzheimer's Disease Therapeutics and Diagnostics Market 2017-2027

LONDON, October 3, 2017 /PRNewswire/ --

Leading Drugs, Pipeline Drugs, Biomarkers, Leading Companies

The Alzheimer's Disease Therapeutics and Diagnostics Market reached $6.71bn in 2016. The Alzheimer's Disease Therapeutics and Diagnostics Market is expected to grow at a CAGR of 15.3% in the second half of the forecast period.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 207-page report you will receive 73 tables and 76 figures- all unavailable elsewhere.

The 207-page report provides clear detailed insight into the Alzheimer's Disease Therapeutics and Diagnostics Market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Alzheimer's Disease Market forecasts  from 2017-2027, further broken down into:
- Alzheimer's Drugs Market
- Alzheimer's Diagnostics Market

• Quantitative analysis of the Alzheimer's drug market from 2017 to 2027. It includes analysis and forecast of top drugs and pipeline drugs in the market:
- Namenda
- Aricept
- Exelon
- Solanezumab
- Gantenerumab
- Verubecestat

• Quantitative analysis of the Alzheimer's diagnostics market from 2017 to 2027. In includes the guidelines and recent research and development in the field of diagnosis. There is further analysis and forecast provided for subsectors of Alzheimer's diagnosis from 2017to 2027:
- Diagnostic biomarker market
- Others

• Profiles of leading pharma companies involved in developing Alzheimer's drugs globally. It contains overviews of the companies' segments, recent mergers and acquisitions and analysis of the companies' recent financial performances. It also includes the details of the drugs for Alzheimer's in the pipeline and forecast of the company drugs available in the market:
- Pfizer
- Eisai
- Actavis
- Lundbeck
- Daiichi Sankyo
- Novartis
- TauRx
- vTv Therapeutics

• Profiles of leading companies developing diagnostics tests for Alzheimer's disease:
- Eli Lilly
- Amarantus Biosciences Holdings
- Piramal Enterprises
- GE Healthcare
- Navidea
- DiaGenic

• This report also breaks down the revenue forecast for the Alzheimer's Disease Market by national market:
- US
- Germany
- France
- Italy
- Spain
- UK
- Japan
- China
- Brazil
- India
- Russia

• This report covers the qualitative analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market. It includes SWOT analysis: Strengths, Weaknesses, Opportunities and Threats of the market.

• This report shows transcripts of research interviews conducted by Visiongain:
- David Hung, Chief Executive Officer of Axovant Sciences Inc.
- Dr. Gill Farrar, PET Neurology, Scientific Director at GE Healthcare
- Phyllis Ferrell, Vice President and Alzheimer's Disease Global Platform Leader at Eli Lilly and Co.

Buy our report today Alzheimer's Disease Therapeutics and Diagnostics Market 2017-2027: Leading Drugs, Pipeline Drugs, Biomarkers, Leading Companies.

To request a report overview of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100

Or click on https://www.visiongain.com/Report/2005/Alzheimer%E2%80%99s-Disease-Therapeutics-and-Diagnostics-Market-2017-2027

List of Companies and Organizations Mentioned in the Report 

AbbVie

AB Science

AC Immune

Acadia Pharmaceuticals

Accera

Actavis

Adamas Pharmceuticals

Affiris

Allergan

Amarantus BioSciences

Amorphis

Amgen

Archer Pharmaceuticals

Astellas Pharma

Astex

AstraZeneca

Avanir Pharmaceuticals

Avineuro Pharmaceuticals

Axovant Sciences Inc

AZ Therapies Inc

Baxter

Bayer

Bayer Schering Pharma

Biogen

bioMerieux

Boehringer Ingelheim

Bristol Myers Suibb

Ceregene

Chiesi Farmaceutici

Cognoptix

Cytos

Daiichi Sankyo

DiaGenic

Eisai

Elan

Eli Lilly

EnVivo Pharmaceuticals

European Medicines Agency (EMA)

Forest Laboratories

Forum Pharmaceuticals

Foundation Medical Partners

Functional Neuromodulation

Food and Drug Administration (FDA)

GE Healthcare

General Electric

Genervon Biopharmaceuticals

Genesys Capital

GSK

Hisamitsu Pharmaceutical

Humanetics

IBA Molecular

J&J

Janssen Alzheimer Immunotherapy Research & Development

Janssen Pharmaceutical K. K

Kareus Therapeutics

LabCorp

Luminex

Lundbeck

Medtronic

Merck & Co

Merz

Meso Scale Diagnostics

Metabolic Solutions Development Company

MorphoSys

Nanotherapeutics

National Institute of Health (NIH)

National Institute for Health and Care Excellence (NICE)

Navidea

NextGen Sciences

Novartis

Novo Nordisk

Ono Pharmaceutical

OPKO

Ortho Clinical Diagnostics

Otsuka Pharmaceutical

Oxford BioDynamics

Par Pharmaceuticals

Pfizer

Piramal Enterprises

Piramal Imaging

Proteome Sciences

ProteoTech

Proterra

QR Pharma

Quanterix

Raptor Pharmaceutical

Resverlogix

Roche

Roche Diagnostics

Saladax

Sandoz

Sangamo BioSciences

Sanofi

sGC Pharma

Shionogi

Shire

Siemens Medical Solutions USA

Somalogic

Sonexa Therapeutics

Sun Pharma

T3D Therapeutics

Takeda

Targacept

TauRx

Toyama Chemical

Transition Therapeutics

TransTech Pharma

United Biomedical

VIVUS

Wyeth

To see a report overview please email Sara Peerun on [email protected]

SOURCE Visiongain Ltd